Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Capricor Therapeutics (CAPR) Equity Average (2016 - 2025)

Capricor Therapeutics has reported Equity Average over the past 15 years, most recently at $194.8 million for Q4 2025.

  • Quarterly results put Equity Average at $194.8 million for Q4 2025, up 82.32% from a year ago — trailing twelve months through Dec 2025 was $194.8 million (up 82.32% YoY), and the annual figure for FY2025 was $225.6 million, up 168.5%.
  • Equity Average for Q4 2025 was $194.8 million at Capricor Therapeutics, up from $94.4 million in the prior quarter.
  • Over the last five years, Equity Average for CAPR hit a ceiling of $194.8 million in Q4 2025 and a floor of $471753.5 in Q3 2023.
  • Median Equity Average over the past 5 years was $30.1 million (2021), compared with a mean of $48.3 million.
  • Biggest five-year swings in Equity Average: tumbled 97.24% in 2023 and later skyrocketed 8354.34% in 2024.
  • Capricor Therapeutics' Equity Average stood at $34.1 million in 2021, then tumbled by 60.04% to $13.6 million in 2022, then dropped by 23.51% to $10.4 million in 2023, then surged by 926.85% to $106.9 million in 2024, then soared by 82.32% to $194.8 million in 2025.
  • The last three reported values for Equity Average were $194.8 million (Q4 2025), $94.4 million (Q3 2025), and $116.3 million (Q2 2025) per Business Quant data.